Inventor · disambiguated record
Kolbot By
Also filed as: BY KOLBOT
12 granted patents·5 pending applications·48 citations·filing 2006–2025
87Inventor score
Files withPRINCIPIA BIOPHARMA INC8ONYX THERAPEUTICS INC4ARYX THERAPEUTICS INC3ALUMIS INC1CORVUS PHARMACEUTICALS INC1
Top patents by PatentIndex Score
17 records- 0190US7326787B2Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disordersARYX THERAPEUTICS INC·Filed 2006·Granted Feb 5, 2008·24 cites·7 claims
- 0288US7629466B2Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disordersARYX THERAPEUTICS INC·Filed 2008·Granted Dec 8, 2009·18 cites·15 claims
- 0382US9315542B2Prodrugs of peptide epoxy ketone protease inhibitorsONYX THERAPEUTICS INC·Filed 2013·Granted Apr 19, 2016·4 cites·30 claims
- 0478US12410176B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Sep 9, 2025·0 cites·1 claims
- 0576US9309283B2Prodrugs of peptide epoxy ketone protease inhibitorsONYX THERAPEUTICS INC·Filed 2013·Granted Apr 12, 2016·2 cites·54 claims
- 0673US12281120B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Granted Apr 22, 2025·0 cites·8 claims
- 0772US2025368656A1Crystalline Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1- YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2- EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2025·Application pending·0 cites
- 0870US2023399330A1Solid Forms of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-d]Pyrimidin-1-YL] Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 0969US11667641B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2021·Granted Jun 6, 2023·0 cites·6 claims
- 1068US11814390B2Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2021·Granted Nov 14, 2023·0 cites·11 claims
- 1167US11708370B2Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2020·Granted Jul 25, 2023·0 cites·16 claims
- 1265US2025376471A1Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrilePRINCIPIA BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1365US2025376459A1Crystalline forms of a tyk2 inhibitor and uses thereofALUMIS INC·Filed 2023·Application pending·0 cites
- 1464US10682419B2Prodrugs of peptide epoxy ketone protease inhibitorsONYX THERAPEUTICS INC·Filed 2018·Granted Jun 16, 2020·0 cites·19 claims
- 1557US2008076927A1Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System DisordersARYX THERAPEUTICS INC·Filed 2007·Application pending·0 cites
- 1656US9878047B2Prodrugs of peptide epoxy ketone protease inhibitorsONYX THERAPEUTICS INC·Filed 2016·Granted Jan 30, 2018·0 cites·13 claims
- 1736US10654825B2Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereofCORVUS PHARMACEUTICALS INC·Filed 2018·Granted May 19, 2020·0 cites·57 claims
Join the waitlist — get patent alerts
Get an alert when Kolbot By files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →